Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35-85
SponsorRarecells Diagnostics SAS
About this trial
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.
This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.
Eligibility criteria
Qualifiers
Male or female aged between 35 and 85 years
Patient diagnosed with resectable lung cancer (by imaging and/or pathological examination) not yet treated for this cancer.
Patient capable of giving free, informed, and express consent
Exclusion of detectable extra thoracic and distant metastases
Disqualifiers
Patient diagnosed and/or treated previously for lung cancer or another cancer, regardless of duration
Patient treated with neoadjuvant treatment
Pregnant women
Patient presenting psychiatric or neurological disorders preventing them from understanding the research
Trial design
Treatments tested in this trial
- CTC-DNA
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov